Rani Therapeutics Holdings Inc expected to post a loss of 31 cents a share - Earnings Preview

Rani Therapeutics Holdings

18/03/2024 20:20

* Rani Therapeutics Holdings Inc  RANI.OQ   RANI.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 20 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Rani Therapeutics
Holdings Inc
is for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rani
Therapeutics
Holdings Inc is $10.00​, above​ its last closing price of $3.32.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.37      -0.36     Beat    1.6
 Jun. 30 2023  -0.35       -0.40      -0.37     Beat    8.5
 Mar. 31 2023  -0.39       -0.41      -0.33     Beat    20.2​
 Dec. 31 2022  -0.36       -0.35      -0.35     Met     -0.6
 ​​Sep.        -0.46       -0.47      -0.33     Beat    29.5
 30 2022                                                
 Jun. 30 2022  -0.52       -0.58      -0.31     Beat    46.3​
 Mar. 31 2022  -0.58       -0.66      -0.29     Beat    56.1
 Dec. 31 2021  -0.65       -0.49      -0.27     Beat    45.5
 This summary was machine generated March 18 at 20:20 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)